Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurothera LabsTSXV:NTLX +12.07%32 EBIT per Share is C$-0.01 as of Dec. 2025. GuruFocus rates TSXV:NTLX with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 812 Drug Manufacturers companies, Neurothera Labs ranks better than 67.24% on this metric.
Neurothera Labs's EBIT per Share for the
three
months ended in Dec. 2025 was C$0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was C$-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 18.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Neurothera Labs's EBIT per Share or its related term are showing as below:
TSXV:NTLX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -81.7 Med: -31.55 Max: 18.6
Current: 18.6
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Neurothera Labs was 18.60% per year. The lowest was -81.70% per year. And the median was -31.55% per year.
TSXV:NTLX's 3-Year EBIT Growth Rate is ranked better than 67.24% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs TSXV:NTLX: 18.60
Neurothera Labs's EBIT for the
three
months ended in Dec. 2025 was C$0.00 Mil.
Neurothera Labs (TSXV:NTLX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Neurothera Labs EBIT per Share Related Terms
Neurothera Labs EBIT per Share Historical Data
* Premium members only.
The historical data trend for Neurothera Labs's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurothera Labs (TSXV:NTLX) has a EBIT per Share of C$-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Neurothera Labs and its competitors. According to the industry distribution chart, Neurothera Labs ranks #266 out of 812 companies in the Drug Manufacturers industry, placing it in the top 32.8%.
Is Neurothera Labs' EBIT per Share too high?
Neurothera Labs' current EBIT per Share is C$-0.01. Based on the distribution chart, Neurothera Labs ranks #266 out of 812 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neurothera Labs has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Neurothera Labs ranks #266 out of 812 companies for EBIT per Share. This puts Neurothera Labs in the upper half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Neurothera Labs and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurothera Labs's current EBIT per Share is C$-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (TSXV:NTLX) has a current EBIT per Share of C$-0.01. The current EBIT per Share is C$-0.01. Neurothera Labs' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Neurothera Labs (TSXV:NTLX), the current EBIT per Share is C$-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
32GF Score
Get the complete analysis for TSXV:NTLX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NTLX has been successfully added to your 
